abemaciclib

Details

Files
Generic Name:
abemaciclib
Project Status:
Active
Therapeutic Area:
Adjuvant treatment of HR-positive, HER2-negative early breast cancer
Manufacturer:
Eli Lilly Canada Inc.
Call for patient/clinician input open:
Brand Name:
Verzenio
Project Line:
Reimbursement Review
Project Number:
PC0345-000
Call for patient/clinician input closed:
Tumour Type:
Breast
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
In combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of disease recurrence based on clinicopathological features.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
​In combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of disease recurrence based on clinicopathological features.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input open24-Oct-23
Call for patient/clinician input closed15-Dec-23
Clarification:

- Patient input submission received from the Canadian Breast Cancer Network and Rethink Breast Cancer

Submission received09-Feb-24
Submission accepted26-Feb-24
Review initiated27-Feb-24
Draft CADTH review report(s) provided to sponsor for comment27-May-24
Clarification:

- Submission temporarily suspended

- Additional information has been received and the temporary suspension of the review has been lifted

Draft CADTH review report(s) provided to sponsor for comment02-Jul-24
Deadline for sponsors comments11-Jul-24
CADTH review report(s) and responses to comments provided to sponsor01-Aug-24
Expert committee meeting (initial)14-Aug-24
Draft recommendation issued to sponsor23-Aug-24
Draft recommendation posted for stakeholder feedback05-Sep-24
End of feedback period19-Sep-24
Final recommendation issued to sponsor and drug plans03-Oct-24
Final recommendation posted22-Oct-24
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)18-Oct-24
CADTH review report(s) posted-